½ÃÀ庸°í¼­
»óǰÄÚµå
1751656

¼¼°èÀÇ ³ë¾È ±³Á¤ ½ÃÀå Á¶»ç º¸°í¼­(2025³â)

2025 Presbyopia Correction Survey Report

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Market Scope, LLC | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Market ScopeÀÇ ÃÊÆÇ ¡¸¼¼°èÀÇ ³ë¾È ±³Á¤ ½ÃÀå Á¶»ç º¸°í¼­(2025 ³â) '´Â Ä¡·á ¹æ¹ý, µµÀÔ °èȹ, Æò±Õ °¡°Ý, ³ë¾È »óȲÀ» Çü¼ºÇÏ´Â »õ·Î¿î ±â¼ú¿¡ ´ëÇÑ ¸Å¿ì Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÇ·á Á¦°øÀÚ, ¿¬±¸ÀÚ, ÅõÀÚÀÚ ¸ðµÎ¿¡°Ô ÁøÈ­ÇÏ´Â ³ë¾È ½ÃÀåÀ» ÀÚ½ÅÀÖ°Ô Å½»öÇϱâ À§ÇØ, º» º¸°í¼­ Ȱ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.

³»¿ë

¾È°ú Àü¹®°¡ÀÇ ±¤¹üÀ§ÇÑ ¼¼°è Á¶»ç µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î, º» º¸°í¼­´Â ¼ö¼ú, Á¦¾à ¹× ±¤ÇÐ ³ë¾È ±³Á¤ ¿É¼Ç¿¡ ´ëÇÑ ±íÀº ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ÇÏÀ̶óÀÌÆ®´Â ´ÙÀ½°ú °°½À´Ï´Ù.

  • Ä¡·á ¼±È£µµ : ÁÖ¿ä ³ë¾È °ü¸® Àü·«ÀÇ ºÐ¼®(¼ö¼ú, ÀǾàǰ, ±¤ÇÐ ¿É¼Ç Æ÷ÇÔ)
  • IOL ½ÃÀå ¿ªÇÐ : Á¦Á¶¾÷ü Æò±Õ °¡°Ý µ¿Çâ, ºê·£µåº° ½ÃÀå Á¡À¯À², ¼ö¼ú ÈÄ Á¶Á¤ °¡´É ¹× Áß°£ ÃÖÀûÈ­ IOLÀÇ ÇâÈÄ Ã¤¿ë °èȹ.
  • ±¼Àý ±³Á¤ ¼ö¼úÀÇ ÅëÂû: ¸ð³ëºñÀüÀÇ ¼±Å÷ü, ³ë¾ÈÀ» Ÿ°ÙÀ¸·Î ÇÑ LVC ¼ö¼úÀÇ 1¾È´çÀÇ ¿ä±Ý, 2025³âÀÇ ¼ö·®À» ¿¹ÃøÇÕ´Ï´Ù.
  • ÀǾàǰ °³¹ß: Vuity³ª Qlosi¿Í °°Àº Á¡¾È¾àÀÇ È¯ÀÚÃþ°ú ó¹æ °æÇâ, Lenz Therapeutics³ª Tenpoint TherapeuticsÀÇ ÇâÈÄÀÇ Ä¡·á¹ýÀÇ ÀÎÁöµµ¿Í ä¿ë µ¿ÇâÀ» ¿¹ÃøÇÕ´Ï´Ù.
  • ¾È°æ ½ÃÀå °³¿ä : ¾È°æ, ¸®´õ, ¿¬¶ôó ½Ã·Â ±³Á¤ Á¡À¯À², ºê·£µå Á¡À¯À², ±³Ã¼ ½ºÄÉÁÙ, ±¸¸Å ºóµµ.
  • ÀÇ»ç°áÁ¤ µå¶óÀ̹ö: »õ·Î¿î Á¡¾È¾à, ·»Áî, ¼ö¼ú±â¼úÀÇ ½ÇÀÓ»ó¿¡¼­ÀÇ Ã¤¿ëÀ» µÞ¹ÞħÇÏ´Â °Í, ȤÀº Áö¿¬½ÃŰ´Â °Í.
>JHS

Market Scope's first-edition "2025 Presbyopia Survey Report" provides pivotal insights into treatment methods, adoption plans, average pricing, and emerging technologies shaping the presbyopia landscape. From drops to presbyopia-correcting IOLs, this report delivers survey data essential for informed decision-making in ophthalmic care. Whether you're a healthcare provider, researcher, or investor, leverage this report to navigate the evolving presbyopia market with confidence.

Contents:

Based on extensive global survey data from ophthalmic professionals, this report provides deep insights across surgical, pharmaceutical, and optical presbyopia correction options.

Key highlights include:

  • Treatment Preferences: Analysis of primary presbyopia management strategies, including surgical, pharmaceutical, and optical options.
  • IOL Market Dynamics: Trends in average manufacturer pricing, market share by brand, and future adoption plans for post-op adjustable and intermediate-optimized IOLs.
  • Refractive Surgery Insights: Monovision selection rates, per-eye fees for LVC procedures targeting presbyopia, and volume expectations for 2025.
  • Pharmaceutical Developments: Patient demographics and prescribing trends for drops like Vuity and Qlosi, plus awareness and adoption projections for upcoming therapies from Lenz Therapeutics and Tenpoint Therapeutics.
  • Optical Market Overview: Share of vision correction across glasses, readers, and contacts-plus brand market share, replacement schedules, and frequency of purchases.
  • Decision Drivers: What drives-or delays-adoption of new drops, lenses, and surgical technologies in real-world practice.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦